6.365  0.095 (1.52%)		04-26 10:28
Open: 6.36 High: 6.39 Volume: 103,081		Pre. Close: 6.27 Low: 6.2901 Market Cap: 5,232(M)

Short term
Mid term
Targets	6-month :	7.96	1-year :	8.58
Resists	First :	6.81	Second :	7.34
Pivot price	6.61
Supports	First :	5.94	Second :	4.95
MAs	MA(5) :	6.36	MA(20) :	6.67
	MA(100) :	8.06	MA(250) :	8.73
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	14.8	D(3) :	14
RSI	RSI(14): 43.6
52-week	High :	12.14	Low :	5.3

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GRFS ] has closed above bottom band by 29.9%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	6.42 - 6.47	6.47 - 6.5
Low:	6.04 - 6.08	6.08 - 6.11
Close:	6.21 - 6.28	6.28 - 6.33

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Tue, 23 Apr 2024
Kepler Capital Sticks to Its Hold Rating for Grifols SA (GRFS) - The Globe and Mail

Mon, 22 Apr 2024
Why Shares of Grifols Were Up Tuesday - The Globe and Mail

Fri, 19 Apr 2024
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire

Mon, 15 Apr 2024
Grifols reportedly looking to appoint independent directors (NASDAQ:GRFS) - Seeking Alpha

Tue, 12 Mar 2024
Should You Hold Grifols SA - ADR ADR Class B (GRFS) Stock Tuesday Morning? - InvestorsObserver

Mon, 11 Mar 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	679 (M)
Shares Float	547 (M)
Held by Insiders	0 (%)
Held by Institutions	49.3 (%)
Shares Short	5,970 (K)
Shares Short P.Month	7,360 (K)

EPS	0.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.57
Profit Margin	0.8 %
Operating Margin	12.7 %
Return on Assets (ttm)	2.1 %
Return on Equity (ttm)	2.2 %
Qtrly Rev. Growth	3.2 %
Gross Profit (p.s.)	0
Sales Per Share	9.7
EBITDA (p.s.)	1.51
Qtrly Earnings Growth	178.6 %
Operating Cash Flow	208 (M)
Levered Free Cash Flow	-1,260 (M)

PE Ratio	63.64
PEG Ratio	0.2
Price to Book value	0.74
Price to Sales	0.65
Price to Cash Flow	20.75

Dividend	0.46
Forward Dividend	0
Dividend Yield	7.2%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.